Vaccine-Derived Polioviruses and Children With Primary Immunodeficiency, Iran, 1995–2014 Publisher Pubmed



Shaghaghi M^{1, 2, 3} ; Shahmahmoodi S^{1, 4} ; Abolhassani H^{1, 2, 3} ; Soleymanjahi S^{1, 2} ; Parvaneh L¹ ; Mahmoudi S⁵ ; Chavoshzadeh Z⁶ ; Yazdani R^{2, 7} ; Zahraei SM⁵ ; Ebrahimi M^{1, 8} ; Eslamian MH^{1, 8} ; Tabatabaie H⁴ ; Yousefi M⁴ ; Kandelousi YM⁴ Show All Authors Show Affiliations
Source: Emerging Infectious Diseases Published:2016

Abstract

Widespread use of oral poliovirus vaccine has led to an ≈99.9% decrease in global incidence of poliomyelitis (from ≈350,000 cases in 1988 to 74 cases in 2015) and eradication of wild-type poliovirus serotypes 2 and 3. However, patients with primary immunodeficiency might shed vaccine-derived polioviruses (VDPVs) for an extended period, which could pose a major threat to polio eradication programs. Since 1995, sixteen VDPV populations have been isolated from 14 patients with immunodeficiency in Iran. For these patients, vaccine-associated paralysis, mostly in >1 extremity, was the first manifestation of primary immunodeficiency. Seven patients with humoral immunodeficiency cleared VDPV infection more frequently than did 6 patients with combined immunodeficiencies. Our results raise questions about manifestations of VDPVs in immunodeficient patients and the role of cellular immunity against enterovirus infections. On the basis of an association between VDPVs and immunodeficiency, we advocate screening of patients with primary immunodeficiency for shedding of polioviruses. © 2016, Centers for Disease Control and Prevention (CDC). All rights reserved.